Allison Swartz Sells 4,657 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 4,657 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Allison Swartz also recently made the following trade(s):

• On Monday, March 2nd, Allison Swartz sold 2,199 shares of Progyny stock. The stock was sold at an average price of $17.27, for a total transaction of $37,976.73.
• On Thursday, December 4th, Allison Swartz sold 530 shares of Progyny stock. The shares were sold at an average price of $24.59, for a total value of $13,032.70.

Progyny Stock Performance

PGNY opened at $17.62 on Friday. Progyny, Inc. has a 52-week low of $16.75 and a 52-week high of $28.75. The firm has a market cap of $1.44 billion, a P/E ratio of 27.11, a price-to-earnings-growth ratio of 1.21 and a beta of 1.01. The business’s fifty day moving average is $23.24 and its 200-day moving average is $22.96.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million during the quarter, compared to the consensus estimate of $314.26 million. During the same quarter in the prior year, the firm posted $0.42 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on PGNY shares. Canaccord Genuity Group boosted their price target on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating on shares of Progyny in a research report on Wednesday, January 21st. Finally, Zacks Research lowered Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $28.80.

Institutional Investors Weigh In On Progyny

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd bought a new stake in Progyny during the fourth quarter valued at $25,000. Cetera Trust Company N.A boosted its position in shares of Progyny by 303.1% during the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after acquiring an additional 985 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after acquiring an additional 819 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in shares of Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after purchasing an additional 894 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.